Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is a common disease in East Asia. Less than 20% of newly
diagnosed patients can undergo radical resection. For those with unresectable BCLC C stage,
transarterial chemotherapy and targeted therapy are recommend to prolong survival. Recently,
FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC)
exhibited high response rate for unresectable HCC. Transartery infusion of agents provide
promising outcome when compared systemic infusion. Furthermore, our pilot study showed TACE
combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.
Whether TACE-HAIC plus hepatic artery infusion PD-1 antibody would improve survival for
unresectalbe BCLC C stage patients is still unknown. A single arm, phase 2 clinical trial is
aimed to answer this question.